| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 51.1B | +4% |
| Gross Profit | 15.9B | - |
| Cost Of Revenue | 35.3B | +5% |
| Operating Income | 2.1B | -8% |
| Operating Expenses | 13.8B | - |
| Net Income | 1.1B | -24% |
| G&A | 4.1B | +7% |
| Amortization | 451MM | -1% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Cigna (CI) closed at $348.78 in the latest trading session, marking a +0.78% move from the prior day.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
As part of its ongoing commitment to community health and vitality, global health company The Cigna Group (NYSE: CI) today announced a multiyear philanthropic and community engagement initiative focused on partnering with nonprofit organizations with expertise in three essential areas: improving youth mental health, bolstering veteran mental health through housing stability and services, and addressing barriers to health equity. As part of this engagement initiative, The Cigna Group Foundation w
Key Insights Cigna Group will host its Annual General Meeting on 24th of April Salary of US$1.50m is part of CEO David...
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The U.S. government is investigating whether the consolidation of health insurers, pharmacy benefit managers and pharmacies is fueling high drug costs. The Department of Health and Human Services’ Office of Inspector General said it is examining whether health insurers' shared ownership of pharmacy-benefit managers and pharmacies has played a role in high drug prices. “We will determine the impact of related entity transactions within select vertically integrated entities on the prices for cov...
Pharmacy benefit managers (PBMs) are in the crosshairs of Republicans and Democrats in Congress but have so far dodged any new litigation or reforms that had been targeted for inclusion in last month's U.S. government budget deal. Many lawmakers, drugmakers and government officials have pointed a finger at these industry middle men, suggesting they play a critical role in high prescription drug costs in the United States. The following is what you need to know about PBMs.
This article delves into the examination of the 14 best 52-week high stocks to buy now. To explore more such companies that meet comparable criteria, go directly to 5 Best 52-Week High Stocks To Buy Now. The outlook for 2024 is positive for the economy and the stock market. Market conditions improved significantly in Q4 […]
Antitrust lawsuits have declined since the pandemic despite a high-profile push by Washington to limit the concentration of power in key industries.
Cigna (CI) reachead $349.84 at the closing of the latest trading day, reflecting a -0.92% change compared to its last close.